| abstract |
The present application relates to conjugates comprising amanita toxin, a target-binding moiety wherein the target is CD20 (ie, a CD20-binding moiety), and optionally a linker connecting said amanita toxin and said CD20-binding moiety . The present invention also relates to the synthesis of said conjugates. Furthermore, the present invention relates to pharmaceutical compositions comprising such conjugates, which are particularly useful in the treatment of B-cell and/or lymphoma-related diseases and/or malignancies. |